Treating patients with HCV genotype 1 and low viraemia: More than meets the eye

Journal of Hepatology

Volumn 44, Issue 1, 2006, Pages 4-7

  Craxì, Antonio ^a,b   Cammà, Calogero ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Gastroenterologia and Epatologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

BODY WEIGHT; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EDITORIAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; VIREMIA; VIRUS LOAD;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; VIREMIA;

EID: 28844446682     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.11.002     Document Type: Editorial

References (19)

1. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
2. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. K.L. Lindsay, C. Trepo, T. Heintges, M.L. Shiffman, S.C. Gordon, and J.C. Hoefs Hepatitis interventional therapy group, a randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395 403
4. S. Zeuzem, S.V. Feinman, J. Rasenack, E.J. Heathcote, M.Y. Lai, and E. Gane Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 2000 1666 1672
5. T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, and G. Ideo Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International hepatitis interventional therapy group (IHIT) Lancet 352 1998 1426 1432
6. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, and V.K. Rustgi Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group N Engl J Med 339 1998 1485 1492
7. G.L. Davis, J.B. Wong, J.G. McHutchison, M.P. Manns, J. Harvey, and J. Albrecht Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
8. P. Ferenci, M.W. Fried, M.L. Shiffman, C.I. Smith, G. Marinos, and F.L. Goncales Jr Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 2005 425 433
9. S.J. Hadziyannis, H. Sette Jr, T.R. Morgan, V. Balan, M. Diago, P. Marcellin, and PEGASYS International Study Group Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
10. S. Magrin, A. Craxì, C. Fabiano, L. Marino, G. Fiorentino, and O. Lo Iacono HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy) J Hepatol 25 1996 583 590
11. T. Berg, C. Sarrazin, E. Herrmann, H. Hinrichsen, T. Gerlach, and R. Zachoval Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy Hepatology 37 2003 600 609
12. N.A. Terrault, J.M. Pawlotsky, J. McHutchison, F. Anderson, M. Krajden, and S. Gordon Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy J Viral Hepatol 12 2005 465 472
13. S. Chevaliez, and J.M. Pawlotsky Use of virologic assays in the diagnosis and management of hepatitis C virus infection Clin Liver Dis 9 2005 371 382
14. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viraemia. J Hepatol 2006; 44: 97-103.
15. A. Mangia, R. Santoro, N. Minerva, G.L. Ricci, V. Carretta, and M. Persico Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 N Engl J Med 352 2005 2609 2617
16. M. von Wagner, M. Huber, T. Berg, H. Hinrichsen, J. Rasenack, and T. Heintges Peginterferon-alpha-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C Gastroenterology 129 2005 522 527
17. K. Lindahl, R. Schvarcz, A. Bruchfeld, and L. Stahle Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia J Viral Hepatol 11 2004 84 87
18. S. Bruno, C. Cammà, V. Di Marco, M. Rumi, M. Vinci, and M. Camozzi Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial J Hepatol 41 2004 474 481
19. P. Pontisso, G. Bellati, M. Brunetto, L. Chemello, G. Colloredo, and R. Di Stefano Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology 29 1999 585 589